EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery - Full Text View - ClinicalTrials.gov
| Official Title: | EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery (IND# 72924): A Phase I Clinical Trial |
This study is not yet open for participant recruitment.
Verified May 2012 by M.D. Anderson Cancer Center
First Received on May 2, 2012.
No Changes Posted
| Sponsor: | M.D. Anderson Cancer Center |
|---|---|
| Collaborator: | Ovarian Cancer Research Fund |
| Information provided by (Responsible Party): | M.D. Anderson Cancer Center ( M.D. Anderson Cancer Center ) |
| ClinicalTrials.gov Identifier: | NCT01591356 |
Purpose
The
goal of this clinical research study is to learn about the safety of
siRNA-EphA2-DOPC when given to patients with advanced, recurrent cancer. Researchers also want to learn the highest tolerable dose of this drug that can be given.
siRNA-EphA2-DOPC is designed to shut down the activity of a gene that causes tumor growth.
